Iloperidone; Zuclopenthixol/Bupropion Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Bupropion may slow down how quickly your liver processes your medicine. Both bupropion and your medicine may make you more susceptible to having a seizure.
What might happen:
The amount of medicine in your blood may increase, which may increase your risk of developing an irregular heartbeat, which may be life threatening. There is also an increased risk that you may have a seizure while taking these medicines together.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change the dose of your medicine. Let your doctor know if you notice an increase in side effects while taking these medicines together, especially any muscle stiffness, confusion, rapid or irregular heartbeat (palpitations), sweating, involuntary movements, dizziness or fainting when getting up from a seated or lying position, or excessive sleepiness. If you have or think you have had a seizure, get medical attention right away.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Fanapt (iloperidone) US prescribing information. Novartis Pharmaceuticals Inc May, 2016.
- 2.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
- 3.Wellbutrin (bupropion hydrochloride) US prescribing information. GlaxoSmithKline November, 2019.
- 4.Zyban (bupropion hydrochloride) US prescribing information. GlaxoSmithKline July, 2019.
- 5.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 6.Clopixol (zuclopenthixol acetate) UK summary of product characteristics. Lundbeck Limited October 15, 2020.
- 7.Cisordinol (zuclopenthixol) Swedish Summary of Product Characteristics. H. Lundbeck A/S May 3, 2014.
- 8.Davies SJ, Westin AA, Castberg I, Lewis G, Lennard MS, Taylor S, Spigset O. Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand 2010 Dec; 122(6):444-53.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.